BigHat Biosciences
An AI and synthetic-biology platform that designs and engineers antibody therapeutics.
$75MSeries C
ParticipantEL
Eli Lilly and Company
Activity from announced rounds
Activity in this selectionSeries C+
Eli Lilly and Company is a medicines developer that also finances external innovation and provides laboratory and development resources to early biotechnology companies.
Its Catalyze360 platform combines several ways to work with a startup. Lilly Ventures provides investment; Lilly Gateway Labs provides laboratory facilities and scientific engagement; Lilly ExploR&D provides research and development capabilities.
The platform engages biotechs at the earliest stages across therapeutic areas. Its investment remit extends into new scientific platforms and health technology, giving founders routes to strategic capital and development infrastructure through different parts of Lilly’s external innovation organisation.
- Rounds participated in
- 4
- Confirmed lead rounds
- 0 2 roles undisclosed
- New companies
- 4 First participation on record · 0 follow-on
- Funding in participating rounds
- $552.5M 4 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
4 in this selectionCircle Pharma, Inc.
Circle Pharma discovers macrocycle medicines for cancer and other serious diseases using its MXMO platform, which combines computational, structure-based design with synthetic chemistry to create cell-permeable compounds against difficult protein targets. Its lead programs are investigational and at discovery or preclinical stages.
$92.5MSeries E
ParticipantRatio Therapeutics
Developing best-in-class radiopharmaceuticals for cancer treatment
$70MSeries C
Role not disclosedAdvanCell
AdvanCell develops targeted alpha radiopharmaceuticals for cancer using Lead-212, with integrated isotope supply and manufacturing.
$315MSeries D
Role not disclosed